Visit https://www.peervoice.com/SEB860 to view the entire programme with slides. After completing “Innovation in Antibody Drug-Conjugate Engineering: Will It Pay Off?”, participants will be able to: Describe the limitations associated with current cancer therapies and the rationale for advancing antibody drug-conjugate (ADC) technology; Summarise the clinical data for the most advanced emerging ADCs in development for solid tumours; Translate how new-generation ADCs could impact current clinical practice

Visit https://www.peervoice.com/YKA860 to view the entire programme with slides. After completing “Scoping Out Optimal Antiviral Therapy for Patients With COVID-19: Exploring the Implications of the Latest Data”, participants will be able to: Summarise the latest clinical data for antiviral therapies in patients with COVID-19; Describe the strengths and limitations of these data within the context of current clinical practice; Discuss how the data on antiviral therapies may inform future clinical considerations in the management of patients with COVID-19

Visit https://www.peervoice.com/TYC860 to view the entire programme with slides. After completing “Taking the Sting Out of Hyperkalaemia: What Clinicians Can Do Now”, participants will be able to: Identify risk factors for hyperkalaemia in patients with chronic kidney disease (CKD) or heart failure (HF); Evaluate the real-world and other data supporting the use of oral potassium-binding agents to manage hyperkalaemia; Apply expert and guideline recommendations for the management and monitoring of hyperkalaemia

Visit https://www.peervoice.com/TAP860 to view the entire programme with slides. After completing “Maintenance Therapy in COPD: Optimising Benefit With Inhalers When Ability to Inhale Is Compromised”, participants will be able to: Define the requirements for effective maintenance therapy in patients with chronic obstructive pulmonary disease (COPD); Identify patients with COPD who require DPI maintenance therapy who have poor inhalation technique or suboptimal peak inspiratory flow rate (PIFR); Distinguish between inhaler therapies based on the need for the patient to have an effective PIFR and inhalation technique with the goal of achieving optimal therapeutic benefit.

Visit https://www.peervoice.com/SEB860 to view the entire programme with slides. After completing “Innovation in Antibody Drug-Conjugate Engineering: Will It Pay Off?”, participants will be able to: Describe the limitations associated with current cancer therapies and the rationale for advancing antibody drug-conjugate (ADC) technology; Summarise the clinical data for the most advanced emerging ADCs in development for solid tumours; Translate how new-generation ADCs could impact current clinical practice.

Visit https://www.peervoice.com/DKF860 to view the entire programme with slides. After completing “Optimising Outcomes With PARPs in Advanced Ovarian Cancer”, participants will be able to: Describe the latest clinical findings for PARP inhibitors in the management of advanced ovarian cancer; Summarise the clinical implications of these emerging data in the management of advanced ovarian cancer; Translate clinical evidence for PARP inhibitors in advanced ovarian cancer into optimal treatment plans.

Visit https://www.peervoice.com/CNT860 to view the entire programme with slides. After completing “Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; Describe the potential clinical implications of novel strategies on outcomes in CKD.

Visit https://www.peervoice.com/TRW860 to view the entire programme with slides. After completing “Taking Aim in Type 2 Diabetes: New Guidelines and Targets for Clinical Practice”, participants will be able to: Describe recent updates in management guidelines for patients with type 2 diabetes (T2DM); Discuss the rationale for these updates in terms of clinical evidence and trial results; Propose individualised, guideline- and evidence-based treatment plans for patients with T2DM.

Visit https://www.peervoice.com/BFC860 to view the entire programme with slides. After completing “Incretin Effect 101: Why We Need to Look Beyond GLP-1 in T2DM”, participants will be able to: Discuss emerging clinical evidence for incretin therapies for type 2 diabetes (T2DM) and how this data may impact future management strategies; Describe the function of incretin hormones and their role in the pathogenesis of T2DM; Recognise the benefits of incretin therapies beyond glycaemic control in patients with T2DM.

Visit https://www.peervoice.com/RNH860 to view the entire programme with slides. After completing “Novel Approaches to Personalized Patient Care in FMF”, participants will be able to: Explain the importance of genetic testing in patients with familial Mediterranean fever (FMF); Discuss key data on biomarkers in FMF and their potential role in clinical practice; Apply strategies for managing patients with FMF to achieve early disease control.